Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.27 USD | -2.73% | -4.23% | -34.48% |
05-09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
05-09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.48% | 936M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Wedbush Lowers Viridian Therapeutics' PT to $37 From $46 on Heels of Leadership Changes, Private Placement; Keeps Outperform Rating